256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. (12th April 2019) - McInnes, Iain B; Kirkham, Bruce; Nash, Peter; Rahman, Proton; Gottlieb, Alice B; Ding, Kevin; Pricop, Luminita